They do have a bye week so that's a startIt's piped to the pumps using existing underground networksCall 0171734 2777 for further informationThe impact on UK mortgage rates is likely to be much more importantSelection currently available at pounds 2pounds 650000 through Knight Frank 0171 629 8171 The situation is certainly ripe for conflict1 per cent growth would project a maturity value 98 per cent higherjiggled around until we got started againThe figures range from Monks the best with a 2With a few more wins "Minotauro" can find himself in a ufc heavyweight champinoship fight.. Once a former pro wrestler, and a collegiate all-american wrestler he has made the transition to mma quite smoothly He won his mma debut by tko in under a 1:10. Randy Couture lost his heavyweight title to Lesnar at UFC 91. Lesnar has made one successful defense so far against Frank Mir. The slated title defense at 106 against Shane Carwin has been postponed until a later event because Lesnar has come down with mononucleosis Arguably, the number 1 p4p fighter in the world He is 31-1 with 1 no contest. 
In the only loss the fight was stopped early because he had a cut above his eye, it was a controversially stoppiage and if it wasn't, the fight could have went the other way. He has notable wins against Antonio Rodrigo Nogueria twice with one no contest, 2 against Mark Coleman, Kevin Randleman, Heath Herring, Ricardo Arona, and Mirko "Cro Cop". He has been critisized for the level of competition he has faced but if he ever comes to the UFC than he will prove that he is the number 1 fighter in the world. Alistair overeem, Junior Dos Santos, Randy Couture, Fabricio Werdum, and Antonio Silva. OAK BROOK, IL, Jan 12 (MARKET WIRE) McDonald's (NYSE: MCD) recently awarded the second-annual U.S.
McDonald's technology suppliers, held at thecompany's Oak Brook, Ill. headquarters.Since 2002, First Data has been a key collaborator in enabling McDonald'sto continuously provide customers with convenient and relevant paymentoptions."First Data has proven integral to the McDonald's system since ourrelationship began six years ago," said David Grooms, Vice President andCIO of McDonald's North America. Technology Supplier of the Year Award is given to thetechnology product supplier that makes the most significant impact on, andcontribution to, McDonald's USA. Thecompany processes transaction data of all kinds, harnesses the power ofthat data and delivers innovations in secure infrastructure, intelligenceand insight for its customers. It powers the global economy by making iteasy, fast and secure for people and businesses around the world to buygoods and services using virtually any form of payment. The company'sportfolio of services and solutions includes merchant transactionprocessing services; credit, debit, private-label, gift, payroll and otherprepaid card offerings; fraud protection and authentication solutions;electronic check acceptance services through TeleCheck; as well asInternet commerce and mobile payment solutions. The company's STARNetwork offers PIN-secured debit acceptance at 2.2 million ATM and retaillocations.Through First Data's centers of excellence, such as security,analytics, customer loyalty and mobile payments, it offers data-drivencommerce solutions for customers around the globe.
restaurants are independently owned and operated by localfranchisees. For more information on McDonald's visit orlog on at any of the 10,000 Wi-Fi enabled McDonald's U.S. restaurants.Copyright 2009 McDonald'sCONTACT:Danya ProudMcDonald's U.S. Media Relations630-623-5063Email ContactElizabeth GriceFirst Data Media Relations303-967-8526Email ContactCopyright 2009, Market Wire, All rights reserved.-0-. Genomic Health Announces Commencement of QUASAR Clinical Validation Study forOncotype DX(R) Colon Cancer Assay- Company to Provide Update on Pipeline Efforts at 27th Annual J.P MorganHealthcare Conference -REDWOOD CITY, Calif., Jan. 12 /PRNewswire-FirstCall/ Genomic Health, Inc.(Nasdaq: GHDX) announced today that it has initiated an independent clinicalvalidation study for its 18-gene Oncotype DX(R) colon cancer assay.Utilizingmore than 1,200 patient samples from the landmark QUASAR trial, the validationstudy will use prospectively defined endpoints to assess the clinical utilityof the Oncotype DX colon cancer assay to predict likelihood of recurrence forstage II colon cancer patients treated with surgery alone and the magnitude oftreatment benefit with chemotherapy following surgery.Results from the studyare expected to be reported in the second half of 2009.Stage II colon cancer (also known as Dukes' Stage B) affects an approximately30-40,000 people each year in the United States and the current treatmentparadigm is unclear.About a third of patients receive adjuvant chemotherapy,usually 5-fluorouracil/leucovorin (5FU/LV) or combinations that include5FU/LV; however, research indicates that only 2-4 percent benefit from thistreatment, which has significant associated toxicity.While there areexisting clinical markers traditionally associated with higher-risk in coloncancer patients, there is no clinically validated genomic test available thatpredicts the likelihood of recurrence or magnitude of chemotherapy benefit forindividual patients."There is a critical need for more targeted approaches in treating the tens ofthousands of patients with stage II colon cancer and the initiation of thisstudy brings us one step closer to delivering a tool that may do that," saidSteven Shak, M.D., chief medical officer, Genomic Health."Over the past twoyears we have partnered with the National Surgical Adjuvant Breast and BowelProject (NSABP) and the Cleveland Clinic Foundation to evaluate more than1,800 patients and 760 candidate genes to select the final 18-gene set for theOncotype DX colon cancer assay.In developing this assay we have applied thesame rigor and technology used to validate the Oncotype DX breast cancerassay, a test that has helped guide treatment decisions for more than 75,000women with early-stage disease."To date, Genomic Health has completed four development studies to identify andselect the 18 genes for the Oncotype DX colon cancer assay.The validationstudy is utilizing samples from QUASAR, the largest study of its kind.Aninternational, multi-center trial, QUASAR examined the benefit associated withadjuvant 5FU/LV for patients with stage II colon cancer.The majority ofsamples for this analysis of the Oncotype DX colon cancer assay are from theUnited Kingdom.Unlike the Oncotype DX breast cancer assay that captures both recurrence andtreatment benefit in one Recurrence Score, the prognostic and predictive genesin the colon cancer assay do not overlap.As such, this colon cancer assaywas designed to generate both a prognostic Recurrence Score and predictiveTreatment Score.Researchers will evaluate the association of the RecurrenceScore with recurrence in stage II colon cancer patients treated with surgeryalone.They will also evaluate the association of the Treatment Score withthe magnitude of chemotherapy benefit in patients treated with adjuvant 5FU/LVchemotherapy."In the absence of reliable prognostic and predictive tools to select stage IIcolon cancer patients for adjuvant chemotherapy, over- and under-treatmentpresent significant challenges," said Alan Venook, M.D., Professor of ClinicalMedicine, Gastrointestinal Oncology Research Program at UCSF Medical Center.
